Rite Aid (RAD) Gets A Boost From JPMorgan Upgrade
Tweet
Share
E-mailGet Alerts RAD Hot Sheet
Price: $0.65 --0%
Rating Summary:
5 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
5 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
Shares of Rite Aid Corp. (NYSE: RAD) are getting a boost today following an upgrade from JPMorgan.
This morning, JPMorgan upgraded the struggling drug store chain from Neutral to Overweight, citing valuation and recent flu trends.
The firm said recent data showing widespread flu instances should drive prescription sales on the pharmacy end of the business and over-the-counter cough and cold products on the front-end of the business.
Shares of Rite Aid are up 4% to $2.72.
This morning, JPMorgan upgraded the struggling drug store chain from Neutral to Overweight, citing valuation and recent flu trends.
The firm said recent data showing widespread flu instances should drive prescription sales on the pharmacy end of the business and over-the-counter cough and cold products on the front-end of the business.
Shares of Rite Aid are up 4% to $2.72.
You May Also Be Interested In
- Nomura/Instinet Upgrades Malayan Banking Bhd (MAY:MK) to Buy
- Citi Upgrades Bapcor Ltd. (BAP:AU) to Neutral
- Citi Upgrades Ming Yuan Cloud Group Holdings Ltd (909:HK) to Buy
Create E-mail Alert Related Categories
Insiders' Blog, UpgradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
